Hello! You're looking at a policy document report on Overton

We track government policy, guidelines, think tank research, working papers and more to help our customers see the impact and influence of their work. Are you interested in seeing what information we have to offer? Request a free trial to our platform.

If you fund, produce or manage research or work to influence policy, we'd love to talk. Learn more on our homepage.

Enabling competition in pharmaceutical markets

Brookings Institution on May 2nd 2017

Fiona Scott Morton and Lysle Boller

The United States, unlike many other industrialized nations, does not regulate the price of pharmaceutical products directly. There are advantages to this approach. The U.S. generic market is one o…

See the 18 policy documents that cite this document

See report on the 18 policy documents that cite this document

See the 13 articles cited by this document

See report on the 13 articles cited by this document

Topics in this document

Generic drug Biosimilar Food and Drug Administration Medication Medicare (United States) Biopharmaceutical Drug Price Competition and Patent Term Restoration Act Epinephrine autoinjector Specialty drugs in the United States Medicare Part D Prescription drug Orphan drug Pharmacy Pharmacology Pharmaceutical sciences Business Healthcare industry Life sciences industry Health care Pharmacy benefit management Pharmaceutical industry Medicine Drugs Economy Health policy Profit (economics) Copayment Health Competition Pyrimethamine

Related SDGs

SDG 3: Good Health and Well-being

Citations

Cited by 18 other policy documents (13 of them are from other policy sources)

This document is made up of multiple PDFs

The references found in each have been combined below. If an item has been cited in more than one PDF then it'll appear more than once, linked to the relevant PDF and page number.